SSH.COM
7.6.2019 09:02:04 CEST | Business Wire | Press release
SSH.COM today announced that their access management gateway solution, PrivX , is now available for free in limited host environments to give IT and software teams all over the world the opportunity to enjoy the benefits of lean, scalable and automated access management to hybrid and multi-cloud (AWS, GCP, Azure, OpenStack) servers and applications.
Cloudification has changed the face of software development and deployment and IT management; modern techniques in software delivery require that trusted access management is in lockstep with development cycles, such as those used in the Continuous Integration/Continuous Delivery (CI/CD) models, while servers are located across on-prem, virtual private cloud (VPC) and multi-cloud environments. Extra steps, bottlenecks and manual processes simply don’t fit into that equation; it’s all about elasticity and automation.
SSH.COM’s Chief Customer Officer, Sami Ahvenniemi: “Spurred on by the shift to the cloud, we have identified that many our customers are looking for the following types of solutions:
- Modern and lean administrative access management tools
- Zero Trust solutions that manage access to critical assets, inside the perimeter
- Automated, scalable alternatives to in-house jump hosts and VPNs
- Centralized 3rd party access controls with monitoring and session recording
The focus is now on the entire access lifecycle of employees, including new hires, people moving around the organization, and people leaving the company. For example, developers, admins and external contractors are all needed - often temporarily - for various tasks with different levels of privilege, all within the critical IT infrastructure. Further, companies and teams often want to start small and scale IT management tools as needed, without taking on the burden of massive IT projects or turning their infrastructure into a hard-to-maintain and complex system. With PrivX, they get an access management solution that deploys in a matter of days, practically updates itself, provides monitoring of access traffic and delivers a simple user experience.”
SSH.COM’s PrivX offers just-in-time role-based access controls to multi-cloud and on-premises resources in development and production environments. Access authorization is never permanent but is based on short-lived certificates that expire within a few minutes of establishing the RDP/SSH connection. PrviX is an agentless and credentialess solution that integrates with existing identity access management (IAM) and directory service (AD/LDAP) tools as well as cloud-hosted servers and applications, including auto-discovery of cloud hosts.
SSH.COM is now making PrivX available free of charge online . Companies can start small and scale with PrivX as their business needs grow.
Mr. Ahvenniemi continued, “Cloud and hybrid environments require technological solutions that emphasize speed and agility over legacy products that are patched up to fit the needs of the cloud. That is why we built PrivX.”
Learn more about PrivX:
- Visit our PrivX product page .
- Download the PrivX datasheet .
- PrivX is reviewed in Kuppinger Cole’s Executive View Report .
- Read about PrivX and its ephemeral certificate-based authentication in our white paper .
About SSH.COM
SSH.COM helps organizations access, secure and control their digital core – their critical data, applications and services. We have over 3,000 customers around the world, including 40 percent of Fortune 500 companies, many of the world’s largest financial institutions, and major organizations in all verticals. We are committed to helping our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction and zero credentials risk. SSH.COM sells online; through offices in North America, Europe and Asia; and through a global network of certified partners. The company’s shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005053/en/
Contact:
SSH.COM Contact : Simo Karkkulainen SSH.COM +358 40 738 9406 simo.karkkulainen@ssh.com SSH.COM Agency Contact : Hanah Johnson March Communications +1 617-960-8892 ssh@marchcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom